Home › Nausea and Vomiting › NCT06585540

A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea And Vomiting in the Bariatric Surgery Population

Who can join

Ages 18 to 65 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* The study will recruit adult patients (Age 18-65) scheduled for bariatric surgery. Additional inclusion criteria include ASA class I-III and patients who plan to be inpatient for at least 24 hours.

Included Surgeries:

Robotic, Laparoscopic or Open Roux-en-Y Robotic, Laparoscopic or Open Gastric Sleeve Robotic, Laparoscopic or Open Gastrectomy Robotic, Laparoscopic or Open Revision Gastric Bypass

Exclusion Criteria:

* Pregnant or breastfeeding
* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
* Congenital QTc abnormalities
* Current use of droperidol
* Parkinson's disease
* Allergy to Barhemsys
* GFR \< 30 mL/min/1.73m2
* Emergency surgery or add-on cases

About the study

To assess the effectiveness of Amisulpride to treat Post Operative Nausea and Vomiting (PONV) and to assess the effectiveness of Amisulpride to prevent PONV following bariatric surgery.

What is being tested

• Amisulpride IV Prevention (drug)
• Amisulpride IV Treatment (drug)
• Placebo Preventative (drug)
• Placebo Treatment (drug)

Sponsor: Benaroya Research Institute · Participants: 100 · Started: Sep 13, 2024

Contact the study team

• Justin S Liberman, Medical Doctor · Phone: 206-341-1298
• David B Auyong, Medical Doctor · Phone: 206-341-1298

Official record on ClinicalTrials.gov — NCT06585540

Locations in the U.S.

Conditions

• Nausea and Vomiting

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.